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Stratiﬁ cation of ROC patients according to length 
of PFI to tailor therapeutic strategies at relapse
The majority (approximately 80%) of patients with ovarian 
cancer will relapse, with a median progression-free survival 
(PFS) of 18 months, and require second-line therapy. Further 
treatment of these patients is complex with several factors 
to be considered, including the length of the platinum-free 
interval (PFI) [1].
The stratiﬁ cation of the ROC patient population into different 
subgroups by PFI (d4 weeks and <6 months, 6-12 months and 
>12 months) is important for deﬁ ning speciﬁ c therapeutic 
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The choice of second-line chemotherapy in patients with recurrent ovarian cancer (ROC) is 
complex, with several factors to be considered, the most important of which is the length of 
the platinum-free treatment interval (PFI). Recently ROC patients have been further stratiﬁ ed 
into platinum sensitive (PS), partially platinum sensitive (PPS) and platinum resistant (PR) 
subgroups depending on the length of the PFI. Response to second-line therapy, progression-
free survival (PFS) and overall survival (OS) are linked to the PFI, all of them improving as 
the PFI increases. Consequently, there is increasing interest in PFI extension strategies with 
platinum-free therapeutic options. Such strategies are currently being studied in patients 
with partially platinum-sensitive disease (PFI 6-12 months), as the treatment of these 
patients remains clinically challenging. A non-platinum option, trabectedin + pegylated 
liposomal doxorubicin (PLD) combination, has been evaluated in ROC patients in the pivotal 
phase III OVA-301 study. The OVA-301 study differed from previous trials in the same setting 
as it included only patients who were not expected to beneﬁ t from or who were ineligible for 
or who were unwilling to receive re-treatment with platinum-based chemotherapy, including 
those with PPS and PR disease. Subset analysis of patients with PPS disease in OVA-301 
showed that the trabectedin + PLD combination signiﬁ cantly improved PFS compared with 
PLD alone; median PFS 7.4 versus 5.5 months, p=0.0152. Final survival data from the same 
subset of patients, showed that trabectedin + PLD also achieved a signiﬁ cant 36% decrease 
in the risk of death compared with PLD alone (HR=0.64; 95% CI, 0.47–0.88; p=0.0027). Median 
overall survival (OS) was 22.4 months in the trabectedin + PLD arm versus 16.4 months in the 
PLD arm. This represents a statistically signiﬁ cant 6-month improvement in median OS in 
patients treated with trabectedin + PLD compared to those treated with PLD alone.
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approaches (Box 1). Clinical studies up until this point have 
classiﬁ ed relapsing patients as having either platinum-
sensitive or platinum-resistant disease.
Rationale for platinum intercalation in PPS 
patients
Response to second-line therapy and prognosis are linked to 
the PFI, with both improving as the PFI increases [3,4]. PFI is 
the most important predictive factor for response to platinum 
retreatment and the most important prognostic factor for PFS 
and overall survival (OS) [3,5,6].
As a result, there is increasing interest in PFI extension 
strategies, including platinum-free therapeutic options. Studies 
evaluating PFI extension strategies with non-platinum drug 
regimens have shown pegylated liposomal doxorubicin (PLD) 
to have equivalent efﬁ cacy and less toxicity compared with 
paclitaxel or topotecan, in patients relapsing after 6 months 
(PLD vs. topotecan: n=122; HR=1.58; p=0.021); however, until 
recently, relatively few studies report separate data for the PPS 
patient population, and the majority of these data are from 
unplanned retrospective subset analyses [7,8].
The clinical management and optimal treatment of the 
partially platinum-sensitive subgroup of ROC patients 
continues to present challenges [4]. Approximately 20% 
of patients with ROC will relapse within the 6-12 month 
period. In vitro and clinical data suggest that extending the 
PFI in patients with relapsed PPS ovarian cancer through 
intercalation of a non-platinum therapy before continuing 
platinum-based regimens at disease progression could be 
clinically beneﬁ cial [9]. In this clinical setting, the potential 
beneﬁ t of artiﬁ cially prolonging the PFI has been evaluated 
in several studies, with data suggesting that extending the 
PFI may restore platinum sensitivity and lead to clinical 
responses or stable disease with platinum retreatment, even 
in heavily pre-treated patients [4,7]. PLD has been included in 
the National Institute for Health and Care Excellence (NICE) 
recommendations as a non-platinum treatment option for 
patients with partially platinum-sensitive disease [10]. A 
head-to-head randomised study has since proven that the 
trabectedin + PLD combination is superior to PLD alone. As a 
result, this guidance is subject to an ongoing NICE appraisal 
(ROC MTA222/91).
Trabectedin + PLD provides one opportunity for 
prolonging the platinum-free interval
Trabectedin (Yondelis®), a marine derived anti-neoplastic 
agent, has been shown to have clinical beneﬁ t in patients 
with ROC. Trabectedin was initially isolated from the tunicate 
Ecteinascidia turbinata and is currently produced synthetically. 
It was ﬁ rst approved in 2007 within the European Union as 
monotherapy for the treatment of patients with advanced 
soft tissue sarcoma (STS). Trabectedin is indicated for the 
treatment of adult patients with advanced soft tissue sarcoma 
after failure of anthracyclines and ifosfamide, or who are 
unsuited to receive these agents [11].
In patients with relapsed, platinum-sensitive ovarian 
cancer trabectedin was approved in combination with PLD 
in 2009. Early phase II trials showed encouraging activity 
as a single agent in patients with relapsed ovarian cancer, 
particularly with platinum sensitive disease, and a large, 
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Fig. 1 – OVA-301: PFS ﬁ nal analysis. Final analysis of progression-free survival in OVA-301by independent radiology [12]. 
Reprinted with permission. © 2014 American Society of Clinical Oncology. All rights reserved.
Box 1 – Identiﬁ able subgroups within the ROC patient 
population [2]
Classiﬁ cations:
• Platinum sensitive (PS) disease: PFI >12 months
• Partially platinum sensitive (PPS) disease: PFI 6 – 12 months
• Platinum resistant (PR) disease: PFI < 6 months
• (Refractory disease: disease progression while receiving the 
last line of platinum therapy or within 4 weeks of the last 
platinum dose)
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multicentre, randomised phase III trial (OVA-301) conﬁ rmed 
that trabectedin + PLD improved PFS over PLD alone (Fig. 1) [12].
PLD was selected as the comparator in this study due 
to its approval as a non-platinum alternative treatment in 
relapsing patients with PPS disease. The trabectedin + PLD 
combination also allowed a lower dose of PLD to be used in 
the combination. The OVA-301 study differed from previous 
trials in the same setting (e.g. CALYPSO) as it included only 
patients who were not expected to beneﬁ t from or who were 
ineligible for or who were unwilling to receive re-treatment 
with platinum-based chemotherapy. The study population 
comprised a total n=672 (made up of the different subgroups 
as follows PR n=242, PS n=216 and PPS n=214).
The results of OVA-301 in the whole study population 
showed that treatment with trabectedin + PLD achieved 
signiﬁ cant beneﬁ ts in terms of PFS, the study’s primary 
endpoint (median PFS: 7.3 months vs. 5.8 months; p=0.019) 
(Fig. 1), ORR (27.6% vs. 18.8%; p=0.008).
The ﬁ nal survival data in the overall study population 
conﬁ rmed the preliminary ﬁ ndings and showed a 14% 
decrease in the risk of death for patients randomised 
to receive the trabectedin + PLD combination (HR=0.86; 
p=0.0835). The median OS in the overall study population 
was 22.2 months for the combination, and 18.9 months for 
PLD alone. However, an unanticipated but signiﬁ cant overall 
imbalance in prognostic factors, including the PFI, was 
found between the two study arms favouring the PLD arm. 
A multivariate analysis based on Cox regression as speciﬁ ed 
in the study protocol was performed and found a relevant 
and signiﬁ cant improvement in OS in the overall population, 
with a 18% decrease in the risk of death in patients treated 
with the trabectedin + PLD combination compared with 
PLD alone (HR=0.82; 22.6 vs. 19.4 months; p=0.0285). These 
ﬁ ndings are in the range of that observed with platinum 
combination therapies [13].
Similar to other studies, further ad hoc analysis of the 
subset of patients with PPS disease (214/672 patients; 32% of 
OVA-301 study population) showed an improved PFS in the 
patients who received the combination compared with PLD 
alone, according to independent radiology review. A 35% risk 
reduction of disease progression (DP) or death was achieved, 
(HR=0.65, 95% conﬁ dence interval (CI), 0.45-0.92; p=0.0152; 
median PFS 7.4 versus 5.5 months). These data compare very 
favourably with the 21% achieved for the overall relapsed 
population [12,14]. The risk reduction of DP or death reached 
46% when these data were evaluated by independent 
oncology review, which included both clinical and imaging 
data [14].
Final survival data in the PPS subset of patients, showed 
that trabectedin + PLD also induced a signiﬁ cant 36% decrease 
in the risk of death compared with PLD alone (HR=0.65; 95% 
CI, 0.47–0.88; p=0.0027). Median OS was 22.4 months in the 
trabectedin + PLD arm versus 16.4 months in the PLD arm; 
a statistically signiﬁ cant 6-month improvement in median 
overall survival was achieved in the patients randomly 
assigned to receive trabectedin + PLD combination therapy 
(Fig. 2) [15].
Similar to the beneﬁ ts in PFS seen in other unplanned ad 
hoc analyses of PPS patients from other studies these ﬁ nal 
survival data from OVA-301 compare very favourably with 
the 16–21 months survival range found in phase II trials 
of other combination chemotherapies, such as PLD plus 
carboplatin or gemcitabine plus PLD [9].
Beneﬁ ts of extending the platinum-free treatment 
interval
Extending the PFI with a non-platinum treatment option, 
such as trabectedin + PLD, may beneﬁ t ROC patients by giving 
them some extra time to recover from the adverse effects of 
their prior platinum-based therapy, while preserving future 
treatment options. These data from OVA-301 demonstrate 
that the PFI can be prolonged in patients with the effective 
non-platinum trabectedin + PLD combination between plati-
num regimens. This translates both in survival advantage 
when reintroducing the subsequent platinum and in recovery 
from previous platinum-induced adverse effects [16].
Clinical evidence supporting subsequent 
platinum rechallenge and observed OS advantage
Further encouraging data in the PPS subgroup from OVA-301 
showed additional beneﬁ ts with the trabectedin + PLD 
combination upon administration of subsequent therapies. 
Differences were particularly pronounced in patients who 
were subsequently rechallenged with platinum as third-line 
therapy after discontinuation of OVA-301. Treatment with 
trabectedin + PLD resulted in a reduction of 42% in the risk of 
death compared with PLD alone (HR=0.58; p=0.0153). Median 
OS for patients receiving trabectedin + PLD was 27.7 months 
compared with 18.7 months for PLD; a notable improvement 
of 9 months in median OS (Fig. 3). Also the patients treated 
with trabectedin + PLD received their subsequent platinum 
later compared with those treated with PLD alone, with 
a median prolongation of the PFI by 4 months (11.5 vs. 
7.5 months; HR=0.61; p=0.0203). The delay in subsequent 
platinum treatment has largely translated into an OS 
extension from previous platinum by a median of 8.9 months 
(18.8 vs. 9.9 months; HR=0.64; p=0.0513) compared with PLD 
alone [16]. This suggests that time off platinum treatment 
may also improve the response to subsequent reintroduction 
of platinum.
One explanation for this is that extending the PFI by an 
effective non-platinum intervention, such as trabectedin + 
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Fig. 2 – OVA-301: Final OS in PPS patients; PFI 6-12 months 
(Ad hoc analysis). Final overall survival in ROC patients with 
partially platinum-sensitive disease from OVA-301. 
© Elsevier [15].
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PLD, may reduce cumulative platinum-induced toxicities, 
which in turn leads to longer survival after the reintroduction 
of subsequent platinum. This is now being explored in a 
prospective randomised trial (which will be discussed in more 
detail later) [16].
The impact of trabectedin plus PLD combination 
on PPS patients’ quality of life
The impact of the trabectedin + PLD combination was also 
assessed on patients’ quality of life (QoL) through patient 
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Fig. 4 – OVA-301: QLQ-C30 global health status scale in the PPS population. Improved QoL for PPS patients randomised to 
receive trabectedin + PLD combination compared with PLD alone [17].
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reported outcomes via QLQ-C30, a standardised QoL instru-
ment developed by the European Organisation for the Research 
and Treatment of Cancer (EORTC) to assess the quality of life 
of cancer patients. Results from OVA-301 showed there was 
a marked improvement in patient-reported functional status 
and symptoms in the PPS patient subgroup receiving the 
trabectedin + PLD combination beyond cycle 5 compared with 
PLD alone (Fig. 4).
As a result the European Society of Medical Oncology 
(ESMO) has issued guidance on the treatment of ROC patients 
with partially platinum-sensitive disease. The trabectedin + 
PLD combination is recommended by ESMO in patients with 
relapsed partially platinum-sensitive ovarian cancer due to 
the observed beneﬁ t in overall survival achieved with the 
combination [18].
On-going clinical trials and future directions
It is likely that the introduction of novel non-platinum based 
chemotherapies and molecular targeted therapies, will have 
a major impact on the management of ROC. Some current 
strategies are focused on the extension of the PFI in patients 
with PS disease, and especially in those with PPS disease as this 
is the group that remains the most clinically challenging [16].
OVA-301 has already demonstrated the survival advantage 
in prolonging the PFI through intercalation of the non-
platinum combination (trabectedin + PLD) between platinum-
based regimens, particularly in the PPS patient subgroup. 
The OS data obtained from OVA-301 demonstrate that the 
combination is signiﬁ cantly superior to PLD monotherapy in 
these patients.
Attention is now turning to a mechanistic rationale to explain 
the observed clinical beneﬁ t. In vitro studies have shown 
platinum resistance to be an unstable, inducible and, possibly, 
reversible phenomenon. Platinum resistance increases after 
each exposure, probably due to the selection of only highly 
resistant cells that are less likely to respond to subsequent 
platinum challenge. The mechanisms for platinum resistance 
are complex and multifactorial. For example, cisplatin-
treated ovarian cancer cells over-express IL-6, and blocking 
IL-6 signiﬁ cantly sensitises platinum-resistant ovarian cancer 
cells to cisplatin. Trabectedin has demonstrated inhibitory 
activity against the production of inﬂ ammatory cytokines, 
such as IL-6, in ovarian cancer cells and tumour-associated 
macrophages (Fig. 5) [19]. Inﬂ ammatory cytokines, such as 
IL-6, are thought to have tumour-promoting actions in the 
ovarian cancer microenvironment [20].
Further in vitro data with trabectedin has also demonstrated 
a treatment ‘sequence effect’, such that trabectedin resistance 
appears to improve sensitivity to platinum in ROC cells (Fig. 6) 
[22].
Resistance to trabectedin is associated with the loss of 
nucleotide excision repair (NER) function, with consequent 
increased sensitivity to cisplatin. This provides the rational 
to test the sequential combination of trabectedin + PLD and 
platinum in the clinic.
Conclusions
In summary, these efﬁ cacy data from the pivotal OVA-301 
study suggest that the trabectedin + PLD combination is an 
effective second-, or any further line, non-platinum treatment 
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option compared with PLD monotherapy for patients with 
ROC unable to continue the next platinum cycle. The observed 
efﬁ cacy and improvement in QoL particularly in patients 
with partially platinum-sensitive disease translates into a 
signiﬁ cant survival advantage, and therefore the combination 
is now recommended by ESMO in this patient subgroup. 
It is thought that by extending the PFI through use of the 
trabectedin + PLD combination allows patients time to recover 
from cumulative platinum-induced adverse effects, which in 
turn leads to longer overall survival after reintroduction of 
subsequent platinum. The trabectedin + PLD combination has 
shifted the treatment paradigm for ROC patients including the 
PPS subgroup or those unsuited to platinum rechallenge, by 
deﬁ ning speciﬁ c therapeutic approaches for these patients. A 
mechanistic rationale is currently being developed to explain 
the observed treatment sequencing effect, particularly in PPS 
patients. Looking ahead, it is anticipated that the ongoing 
INOVATYON study, comparing the non-platinum trabectedin 
+ PLD with a platinum + PLD combination will conﬁ rm this 
hypothesis and provide guidance regarding the treatment 
sequence beneﬁ ts in managing ROC patients, particularly in 
the PPS subgroup.
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